Your browser doesn't support javascript.
Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study.
Soliman, Ashraf T; Prabhakaran Nair, Arun; Al Masalamani, Muna S; De Sanctis, Vincenzo; Abu Khattab, Mohamad A; Alsaud, Arwa E; Sasi, Sreethish; Ali, Elrazi A; Ola A, Hassan; Iqbal, Fatima M; Nashwan, Abdulqadir J; Fahad, Jesin; El Madhoun, Ihab; Yassin, Mohamed A.
  • Soliman AT; Pediatric and Endocrinology, Hamad General Hospital, Doha, Qatar . Atsoliman@yahoo.com.
  • Prabhakaran Nair A; Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. anair9@hamad.qa.
  • Al Masalamani MS; Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. MALMASLAMANI@hamad.qa.
  • De Sanctis V; Quisisana Hospital, Ferrara. vdesanctis@libero.it.
  • Abu Khattab MA; Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. MABUKHATTAB@hamad.qa.
  • Alsaud AE; Department of Endocrinology and Diabetes, Hamad Medical Corporation (HMC), Doha, Qatar. arwa.alsaud@gmail.com.
  • Sasi S; Internal Medicine Dept., Hamad General Hospital (HGH), Hamad Medical Corporation (HMC), Doha, Qatar. SSasi7@hamad.qa.
  • Ali EA; Internal Medicine Dept., Hamad Medical Corporation (HMC), Doha, Qatar. EAli14@hamad.qa.
  • Ola A H; Medical Resident, Family Medicine, Medical Education, Hamad Medical Corporation (HMC), Doha, Qatar. ola.gornass@hotmail.com.
  • Iqbal FM; Infectious Diseases, Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. fiqbal1@hamad.qa.
  • Nashwan AJ; Hazm Mebaireek General Hospital (HMGH), Hamad Medical Corporation (HMC), Doha, Qatar. anashwan@hamad.qa.
  • Fahad J; Quality Management Data Analyst, Communicable Disease Center (CDC), Hamad Medical Corporation (HMC), Doha, Qatar. Jesyfax@gmail.com.
  • El Madhoun I; AlWakra Hospital, Hamad Medical Center. ielmadhoun@hamad.qa.
  • Yassin MA; National Center for Cancer care and Research, Doha, Qatar. . yassinmoha@gmail.com.
Acta Biomed ; 91(3): e2020010, 2020 09 07.
Article in English | MEDLINE | ID: covidwho-761250
ABSTRACT

BACKGROUND:

There is a scarcity of data regarding the effect of Type 2 diabetes mellitus (T2DM) and associated comorbidities on the clinical presentation and outcome of symptomatic patients with -COVID-19 infection in comparison with non-diabetic patients. AIM OF THE STUDY We described and compared the clinical presentation and radiological and hematological data of a cohort of symptomatic COVID19 positive T2DM diabetic patients (n = 59) versus another cohort of non-diabetic symptomatic COVID19 positive patients (n =244) diagnosed at the same time from January 2020 to May 2020. Associated comorbidities were -assessed, and the Charlson Comorbidity Index was calculated. The outcomes including duration of hospitalization, duration of Intensive Care Unit (ICU) stay, duration of mechanical ventilation, and duration of O2 -supplementation were assessed.

RESULTS:

Prevalence of T2DM in symptomatic COVID19 positive patients was 59/303 (=19.5%).  Diabetic patients had higher prevalence of hypertension, chronic kidney disease (CKD) and cardiac dysfunction [coronary heart disease (CHD)], and congestive heart failure (CHF). Charlson Comorbidity score was significantly higher in the T2DM patients (2.4± 1.6) versus the non-diabetic -patients (0.28 ± 0.8; p < 0.001). Clinically and radiologically, T2DM patients had significantly higher percentage of pneumonia, severe pneumonia and ARDS versus the non-diabetic patients. Hematologically, diabetic patients had significantly higher C-reactive protein (CRP), higher absolute neutrophilic count (ANC) and lower counts of lymphocytes and eosinophils compared to non-diabetic patients. They had significantly higher systolic and diastolic blood pressures, longer duration of hospitalization, ICU stay, mechanical ventilation and oxygen therapy. CRP was correlated significantly with the duration of stay in the ICU and the duration for oxygen supplementation (r = 0.37 and 0.42 respectively; p <0.01).

CONCLUSIONS:

T2DM patients showed higher inflammatory response to COVID 19 with higher absolute neutrophilic count (ANC) and CRP with lower lymphocytic and eosinophilic counts. Diabetic patients had more comorbidities and more aggressive course of the disease with higher rate of ICU admission and longer need for hospitalization and oxygen use.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / C-Reactive Protein / Coronavirus Infections / Diabetes Mellitus, Type 2 / Pandemics / Betacoronavirus / Intensive Care Units Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Acta Biomed Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Abm.v91i3.10214

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / C-Reactive Protein / Coronavirus Infections / Diabetes Mellitus, Type 2 / Pandemics / Betacoronavirus / Intensive Care Units Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Acta Biomed Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Abm.v91i3.10214